Bristol-Myers Squibb Company
Research Bristol-Myers Squibb Company (BMY) on Bullrun: valuation model: 2.6% undervalued, market cap USD 138.76B, P/E 15.0, dividend yield 3.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBMY
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal2.6% undervalued
- Market capUSD 138.76B
- P/E15.0
- Dividend yield3.8%
- Financial periodQ2 2026
- RevenueUSD 12.97B
- Net incomeUSD 3.32B
- Free cash flowUSD 3.09B
- Gross margin71.3%
Valuation Snapshot
Bullrun's latest valuation model marks Bristol-Myers Squibb Company as 2.6% undervalued; latest market cap is USD 138.76B; P/E is 15.0; dividend yield is 3.8%.
Peer valuation comparison
Latest P/E is 14.96x versus a Healthcare sector median of 24.46x (38.8% below).
Latest dividend yield is 3.75% versus a Healthcare sector median of 2.11% (77.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 48.19B | USD 7.05B | USD 12.85B | 71.1% | 3.46 | USD 10.21B | USD 45.11B | USD 18.47B |
| FY2024 | USD 48.30B | -USD 8.95B | USD 13.94B | 71.1% | -4.41 | USD 10.35B | USD 49.65B | USD 16.34B |
| FY2023 | USD 45.01B | USD 8.03B | USD 12.65B | 76.2% | 3.86 | USD 11.46B | USD 39.77B | USD 29.43B |
| FY2022 | USD 46.16B | USD 6.33B | USD 11.95B | 78.0% | 2.95 | USD 9.12B | USD 39.32B | USD 31.06B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 138.76B | 15.0 | 3.7% | 2.51 |
| 2025 | 2025-12-31 | USD 109.81B | 15.6 | 4.6% | 2.48 |
| 2024 | 2024-12-31 | USD 114.76B | n/a | 4.2% | 2.4 |
| 2023 | 2023-12-29 | USD 104.40B | 13.0 | 4.4% | 2.28 |
| 2022 | 2022-12-30 | USD 152.98B | 23.4 | 3.0% | 2.16 |
| 2021 | 2021-12-31 | USD 134.24B | 20.0 | 2.4% | 1.47 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.51 USD, yield 3.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 2.49 USD |
| FY2024 | 2.42 USD |
| FY2023 | 2.31 USD |
| FY2022 | 2.19 USD |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Bristol-Myers Squibb Company overvalued or undervalued?
Bullrun's valuation model currently marks Bristol-Myers Squibb Company as 2.6% undervalued.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company's market capitalization is USD 138.76B.
What is Bristol-Myers Squibb Company's P/E ratio?
Bristol-Myers Squibb Company's price-to-earnings (P/E) ratio is 15.0.
Does Bristol-Myers Squibb Company pay a dividend?
Bristol-Myers Squibb Company has a dividend yield of 3.8%.
What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.